Author:
Yu Liqun,Wang Lawrence,Mao Chengjian,Duraki Darjan,Kim Ji Eun,Huang Rui,Helferich William G.,Nelson Erik R.,Park Ben Ho,Shapiro David J.
Funder
National Institutes of Health
National Center for Complementary and Integrative Health
U.S. Department of Defense
Office of Dietary Supplements
National Cancer Institute
Reference51 articles.
1. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer;Clark;J. Clin. Oncol.,1984
2. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study;Fisher;J. Natl. Cancer Inst.,1998
3. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment;Howell;J. Clin. Oncol.,2002
4. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen;Dowsett;J. Clin. Oncol.,2009
5. Biological determinants of endocrine resistance in breast cancer;Musgrove;Nat. Rev. Canc.,2009
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献